• Explore /
  • Poster
  • / A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).

A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).

Abstract Poster

Authors

null

Andrew X. Zhu

Massachusetts General Hospital Cancer Center, Boston, MA

Andrew X. Zhu , Peter R. Galle , Masatoshi Kudo , Richard S. Finn , Ling Yang , Paolo Abada , Shao-Chun Chang , Josep M. Llovet

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02435433

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS478)

DOI

10.1200/jco.2016.34.4_suppl.tps478

Abstract #

TPS478

Poster Bd #

O6

Abstract Disclosures

Similar Posters

First Author: Andrew X. Zhu

First Author: Andrew X. Zhu

First Author: Ian Chau

First Author: Maria Reig